The Villages, FL, United States of America

John G Gleason

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Aldeyra Therapeutics, Inc.. Active years: 2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John G Gleason. Retrieved from https://idiyas.com/inventor/john-g-gleason-6vf64fww

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 77(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: John G Gleason: Innovator in Macular Degeneration Treatment

Introduction

John G Gleason is a notable inventor based in The Villages, FL (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of macular degeneration. His innovative approach has led to the development of a unique patent that addresses this critical health issue.

Latest Patents

John G Gleason holds a patent for "Traps in the treatment of macular degeneration." This invention is directed to compounds of formula (A), which includes pharmaceutical compositions and methods of use for treating, reducing a symptom of, or reducing the risk of macular degeneration. His work in this area is crucial for advancing treatment options for patients suffering from this condition. He has 1 patent to his name.

Career Highlights

Gleason is associated with Aldeyra Therapeutics, Inc., a company dedicated to developing innovative therapies for ocular diseases. His role at the company has allowed him to focus on groundbreaking research and development in the field of eye health.

Collaborations

Throughout his career, John G Gleason has collaborated with esteemed colleagues, including John Clifford Chabala and Thomas A Jordan. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

John G Gleason's contributions to the treatment of macular degeneration highlight his commitment to improving patient outcomes through innovative pharmaceutical solutions. His work continues to inspire advancements in the field of ocular health.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…